Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on integrin-based treatments for serious diseases. Pliant has no approved products and generates no product revenue. Its lead candidate, PLN-101095, is an oral small molecule that inhibits two integrins — αvβ8 and αvβ1 — which activate TGF-β, a signaling molecule that suppresses immune activity in tumors. By blocking these integrins, PLN-101095 aims to reduce TGF-β-driven immune suppression in the tumor microenvironment, potentially restoring tumor sensitivity to immune checkpoint inhibitors (ICIs). The target population is solid tumor patients whose cancers have stopped responding to ICIs. PLN-101095 is currently in Phase 1, where early data showed 4 of 10 ICI-refractory patients responded when treated in combination with pembrolizumab, with responding patients showing 4- to 13-fold increases in plasma interferon gamma, a biomarker of immune activation. Pliant plans to initiate a Phase 1b expansion trial in NSCLC and other tumor types in 2026. Beyond PLN-101095, Pliant maintains a drug discovery platform of over 15,000 proprietary integrin-binding molecules, with early preclinical programs exploring targeted drug delivery to specific cell types. A prior program targeting pulmonary fibrosis was discontinued in 2025 after a safety review. Pliant funds operations through equity financing and intends to partner with larger companies for major indications and ex-North America geographies, while retaining rights in smaller indications or North America.